Purpose: This study is designed to estimate the prevalence of epilepsy associated with TSC in Sweden and to describe treatment, morbidity, and mortality of TSC patients with epilepsy. Methods: Register data for 2004-2014 was obtained from the National Board of Health and Welfare in Sweden. Patients with TSC were identified using ICD-10 codes. Epilepsy was identified using ICD-10 codes, interventions aimed to treat epilepsy, or prescriptions for antiepileptic drugs. Results: The prevalence of TSC was 5.38 per 100 000 individuals. We identified 551 unique patients with TSC, of which 386 (70.1%) had epilepsy. The mean study period was 8.82 years. Antiepileptic drugs were dispensed to 97.9% of patients with epilepsy. The most prescribed antiepileptic drug was sodium valproate. Ketogenic diet was used in 6 (1.6%) patients, vagus nerve stimulation in 23 (6.0%) patients, and epilepsy surgery was performed in 25 (6.5%) patients. The mean number of outpatient visits per year was 4.70 (SD 4.17) and the mean number of inpatient days per year was 3.25 (SD 5.61). The mean number of outpatient visits per year with an ICD-10 code for epilepsy was 1.65 (SD 1.95) and the corresponding number of inpatient days was 2.06 (SD 4.50). A total of 30 patients with TSC and epilepsy died during the study period. Conclusions: The prevalence of epilepsy in this study was in the lower range of previously reported numbers, suggesting that epilepsy may be overestimated in non-population based studies. A substantial part of the healthcare utilization was directly related to epilepsy.
Introduction
Tuberous sclerosis complex 1 (TSC) is a rare genetic disorder characterized by the presence of benign tumors (hamartomas) in multiple organs, including the brain, kidneys, heart, and skin [1] . In 85-90% of the patients with a clinical diagnosis of TSC, a pathogenic mutation is found in either of the tumor suppressor genes TSC1 or TSC2 [2, 3] . In the remaining patients, it has been suggested that the mutation is mosaic or in non-coding regions of these genes, suggesting there are no other TSC genes [4] . TSC can be inherited, but is a de novo event in the majority of patients [5] . Cortical tubers, subependymal nodules (SEN), and subependymal giant cell astrocytomas (SEGA) are neuropathological hallmarks of TSC. The presence of cortical or subcortical tubers is associated with the development of epilepsy, which is the most common neurological manifestation of TSC, with a reported prevalence as high as 90% in some studies [5] [6] [7] . Epilepsy is already present at the time of TSC diagnosis in up to two thirds of the patients, as it often debuts during the first year of life with focal seizures or epileptic spasms (spasms occurring in infancy are referred to as infantile spasms; IS) [5] . Multiple seizure types may develop, and seizures are often refractory to treatment [2, 5, 8, 9] . The early onset and refractory nature of epilepsy in TSC is of concern, as there is a correlation between severe/early on-set epilepsy and intellectual disability, underlining epilepsy as a major cause of morbidity in the TSC population [3, 5, 7] . Treatment options for epilepsy associated with TSC generally mirrors that of epilepsy in the general population. First-line treatment is an anti-epileptic drug (AED) and second-line treatment combines AEDs [10] . The use of ketogenic diet, vagus nerve stimulation (VNS), and epilepsy surgery are treatment options of refractory epilepsy [2, [9] [10] [11] [12] . The mutation in TSC1 or TSC2 leads to insufficient suppression of the mechanistic target of rapamycin (mTOR) complex-1 (mTORC1) pathway, which results in the growth of hamartomas [3] . Inhibiting the mTORC1 pathway is a viable approach for the treatment of TSC associated epilepsy. Recent evidence supports mTOR-inhibitors as adjunctive treatment to AEDs for treating epilepsy in TSC patients [13] . Given the prevalence and severity of TSC-associated epilepsy there is a need to study patients with the condition in any given setting. The aim of this study is to describe prevalence, manifestations, treatments, healthcare utilization, and mortality of TSC patients with epilepsy in Sweden using population based registers.
Material and methods

Study design
This study used registers held by the National Board of Health and Welfare (NBHW) to study patients with TSC and epilepsy. The selected registers included a national in-and outpatient register (National Patient Register, NPR), the national Prescribed Drug Register (PDR), and the national Cause of Death Register (CDR). The registers contain healthcare visits, all dispenses of prescribed pharmaceuticals, and mortality including causes of death. All selected registers are national with mandatory reporting for healthcare providers and pharmacies. The NBHW reports close to complete coverage with 99% of inpatient discharges being recorded and only 1-2% missing in the CDR [14, 15] .
The NPR contains data on all healthcare utilization except primary care, including length of stay, International Classification of Diseases (ICD-10) codes, and procedure codes. The PDR contains data on the date of prescription, dispense, and Anatomical Therapeutic Chemical (ATC) codes of all dispensed drugs. Nonprescription pharmaceuticals and pharmaceuticals distributed to patients within healthcare institutions are not included in the PDR. The CDR contains data on underlying and accompanying cause of death along with supporting information such as recent surgical procedures.
Individuals were identified in the NPR. All patients with an ICD-10 code for TSC, Q85.1, from the 1st of January 2004 to the 31st of December 2013 were included. Epilepsy was defined as at least one occurrence of an ICD-10 code for epilepsy, G40.* or G41.*, a procedure directly related to epilepsy (VNS, ketogenic diet, or epilepsy surgery), or retrieval of an AED, ATC-code: N03A*.
For the identified individuals, all pharmaceutical dispenses, healthcare visits (inpatient and outpatient), and deaths were extracted from the PDR, NPR, and CDR. All data in the study period was obtained, regardless of when the first TSC or epilepsy observation was identified.
Study period
The study period was the 1st of January 2004 to the 31st of December 2014. Due to differences in availability, update frequency, and latency, all registers did not cover the entire period. The actual study period for each register is depicted in Fig. 1 . Individuals were identified as having TSC in the NPR, i.e. the identification period corresponds to the study period for the NPR. The PDR did not include the Swedish personal identification number prior to 1st of July 2005, only allowing for coupling with the NPR after that date. The CDR lacks specific data on cause of death for 2014 as this is updated retrospectively and was not available at the time of data extraction.
Analysis
For the identified population we studied the prevalence of TSC manifestations, pharmaceutical utilization, healthcare utilization, non-pharmaceutical procedures, and mortality. The prevalence of TSC and epilepsy is limited to clinically relevant cases as only patients with at least one corresponding healthcare visit are included. Refractory epilepsy was defined as having more than two simultaneous AEDs for at least 91 days, corresponding to at least two consecutive prescription periods [16] . Prescribed pharmaceuticals were defined using ATC-codes. Specific attention was paid to drugs relating to the nervous system: AEDs (N03A*), neuroleptics (N05A*), anxiolytics (N05B*), and psychoanaleptics (N06*). Use of mTOR inhibitors was also captured. Any retrieval of AEDs (N03A*) was assumed to last for 90 days according to national recommendations [17] .
Healthcare utilization was defined as the number of outpatient visits and inpatient days during the study. General healthcare and episodes with a diagnosis of epilepsy were recorded separately. The number of outpatient visits and inpatient days per year is presented as means with standard deviations. Healthcare per year was only calculated for individuals with a study period of at least 90 days in the NPR.
Non-pharmaceutical procedures and interventions were identified using procedure codes (KVÅ/KKÅ). The number of individuals with surgery due to epilepsy, subependymal giant-cell tumors (SEGA), or renal complications was recorded. Individuals with VNS or ketogenic diet were also recorded.
Mortality and underlying cause of death were captured in the CDR.
In addition to the entire population we also studied the data grouped by age at first observation, presence of refractory epilepsy, patients with focal seizures, and patients with infantile spasms. We use the term infantile spasms for infants with epileptic spasms as suggested by the International League Against Epilepsy (ILAE) [18] . The exact definitions of manifestations, pharmaceuticals, healthcare, and procedures are presented in Table 1 .
Results
Prevalence and patient characteristics
A total of 551 individuals with a diagnosis of TSC were identified in the NPR. Of these, 386 patients had epilepsy. Based on the population in Sweden at the end of 2013 the prevalence of TSC was calculated to 5.38 per 100 000 individuals. The prevalence of epilepsy among patients with TSC was 70.1%. Among patients with TSC identified before age 20 the prevalence of epilepsy was 74.5% Patient characteristics and manifestations of TSC are presented in Table 2 . The mean study period, defined as time from first to last observation in the registers, was 8.82 years. Over 75% of patients were observed for more than 8 years. The theoretical maximum study period was 11 years. The median age at first observation in the NPR was 13 years, (Q1-Q3 2.25-27.00) with the majority of patients below 20 years of age. The epilepsy population was divided into patients with and without focal seizures. At least one focal seizure was recorded in 224 (58.0%) patients. A diagnosis of IS was found in 19 individuals aged 0-2. This translates to a 19.2% prevalence of IS among individuals observed from 0 to 2 years of age. Two additional patients, aged 10 and 13 years, were found with ICD-10 codes for IS and were excluded from the subgroup due to their age. The criteria for refractory epilepsy was fulfilled for 127 (32.9%) patients.
Treatment
The most common pharmaceutical treatment was AEDs with 97.9% of patients having a prescription at some point during the study period. The second most common pharmaceutical treatment was anxiolytics in 72.5% of the patients. However, most anxiolytics were benzodiazepines, typically used as acute seizure terminating therapy. As the analysis is based on ATC-codes we have not verified the formula to correspond to seizure terminating therapy. The Data management and analysis was performed using R, version 3.3.1 [19] . pharmaceutical groups presented in Table 3 make up 62.5% of all prescriptions during the study period. AEDs were the most diverse pharmaceutical group with multiple substances being used by the majority of patients. The most commonly used AEDs, dispensed at least once, were sodium valproate (45.1%), lamotrigine (43.3%), carbamazepine (37.6%), levetiracetam (36.5%), and topiramate (24.1%). mTOR-inhibitors (everolimus and sirolimus) were used in 15.3% of patients, although the indication for use was not analysed.
The number of patients with non-pharmaceutical treatments and surgery are presented in Table 4 . Epilepsy surgery, VNS, and ketogenic diet are all options for the treatment of refractory epilepsy. In addition, the number of SEGA surgeries is also reported.
Most epilepsy surgeries are performed in young patients and epilepsy surgery, VNS, and ketogenic diet are most common in patients with refractory epilepsy.
Healthcare resource utilization
Healthcare utilization is divided into outpatient and inpatient care. As the data extraction is not limited to healthcare utilization related to epilepsy, we present visits with an ICD-10 code for epilepsy separately. We found that 87.8% of the patients had an outpatient visit with an ICD-10 code identifying epilepsy. The corresponding inpatient proportion was 59.8%. The mean annual resource utilization over the entire study period is presented in Table 5 . Patients with IS, refractory epilepsy, and young patients had the highest mean healthcare utilization. This pattern holds for all four categories of healthcare utilization.
Mortality
A total of 30 (7.8%) patients in the epilepsy population died during the study period. In five of the cases the cause of death is unknown, as it had not yet been made available at the time of data extraction. The cause of death was directly related to the TSC diagnosis in 15 (50.0%) cases, including three cases where epilepsy was deemed causative, and probably TSC-related in seven (23.3%) cases (tumors).
Discussion
This retrospective study identified 551 unique patients with TSC. Using the NPR database, we are convinced that all TSC patients with a clinically relevant disease burden have been included. At the end of 2013, 519 were alive, which corresponds to a prevalence of clinically relevant TSC of 5.38 per 100 000 individuals. This is in line with previously published prevalence figures [3, 7, 8, 20, 21] . Approximately 70% of the patients with TSC also had an epilepsy diagnosis. The prevalence of epilepsy in the TSC population is difficult to estimate due to selection bias and the estimate being sensitive to the identification method [5] . The epilepsy prevalence among patients with TSC in this study is in the lower range of previous reports [5, 8] . This suggests that non-population based approaches may overestimate the prevalence, possibly due to referral (selection) bias.
Most major manifestations were present in the epilepsy population, but cognitive and neurodevelopmental problems dominated. Other manifestations such as skin lesions, SEGA, SEN, and angiomyolipoma of the kidney were considerably lower than in the recent publication from the TOSCA register [8] . Two reasons for this may be: (i) the NPR only includes ICD codes directly related to each visit, and (ii) clinicians underreport relevant ICD-10 codes. This would explain the lower prevalence estimates for these manifestations. It is possible that the surveillance was limited during the study as the guidelines for diagnosis and surveillance were adopted in 2013 [22] .
IS occurred in 19 out of 99 patients aged between 0 and 2 years during the study period. This is somewhat lower than in prior studies [3, 23] . Since IS require inpatient care, the NPR should be sufficient to identify all cases during the study period. It is difficult to explain the lower estimate. Plausible explanations are inaccurate ICD-10 coding, the possibility of younger patients suffering from IS before the study period, or overestimates in previous studies due to selection bias. Occurrence before the study period is however only possible for a subset of the patients at risk for IS, as most were born during the study period. Two children were found with diagnoses of IS after the age of two, but were not included in the IS group. Epileptic spasms may occur in a subset of older TSC patients, often in the setting of other seizure types and refractory epilepsy, possibly explaining the coding [24] . Earlier studies report that IS in TSC predicts the development of refractory epilepsy [3] . Refractory epilepsy is strongly connected to TSC associated neuropsychiatric disorders (TAND) and cognitive deficit. This emphasizes the need for a better understanding and treatment of this group of patients to possibly avoid severe developmental issues in the future [25] .
The most commonly prescribed AEDs were sodium valproate, carbamazepine, lamotrigine, levetiracetam, and topiramate. Current European guidelines recommend the use of vigabatrin in the treatment of both epileptic spasms and focal seizures in infants [10] . Vigabatrin was used by 22.5% of patients at some point during the study, making it the sixth most common AED. One possible explanation why it is not more common may be visual field constriction, a well-known side effect of vigabatrin, possibly making the clinician prefer other AEDs [8] . The use of AEDs to treat epilepsy associated with TSC in Sweden is similar to other countries [8, 20] . Since almost all TSC patients with epilepsy in our study were treated with at least one AED, there may be a possibility to estimate the prevalence of epilepsy in a TSC population based merely on a TSC diagnosis in combination with an AED prescription.
The estimated proportion of patients with refractory epilepsy is in line with some previous studies, but higher numbers have been reported [3, 8] . There is a possibility that the refractory epilepsy is overestimated for some patients and underestimated for others as the registers do not allow for identification of individual seizures. Despite one third of the TSC patients with epilepsy being estimated to have refractory epilepsy, adjunct non-pharmacological therapies were rare. This study specifically looked at ketogenic diet (n = 6, 1.6%), epilepsy surgery (n = 25, 6.5%), and VNS (n = 23, 6.0%). Similar findings were reported for the cohort in TOSCA [8] . Nevertheless, these interventions are not always straightforward; several potential epileptic foci often exist when considering surgery and there are strict requirements for ketogenic diet [5] . There is also a paucity of data regarding their effectiveness in this population [2, 5, [9] [10] [11] [12] .
While studying underlying cause of death only provides a coarse illustration of mortality, TSC was an underlying factor in the majority of deaths. Epilepsy was the underlying cause in three deaths, which stresses its role in the elevated mortality risk among patients with TSC [6, 26] . It was not possible to assign the tumorrelated deaths directly to TSC in this study, but considering the nature of TSC, a connection is plausible. Previous findings together with this study indicate that epilepsy associated with TSC not only leads to high morbidity but also affects mortality. Limitations regarding this study include the used registers. While generally reliable, it is possible that records contain errors due to inaccurate coding, misdiagnosis, or other reasons. Additionally, the description of healthcare utilization is not complete since the NPR does not include primary care data. Any drugs solely used in a hospital setting, i.e. not dispensed from a pharmacy, are not included in the PDR. The prevalence figures could be underestimated since asymptomatic cases and patients with mild, or successfully controlled, disease may not have had any healthcare contacts that can be identified in the NPR.
Conclusion
The Swedish national health data registries allow for the description of the total symptomatic epilepsy population associated with TSC. The prevalence of epilepsy in TSC, treatment patterns, and the estimated proportion of patients with refractory epilepsy agree with previous findings in other countries but are generally lower. The burden of disease in this population is high with patients experiencing cognitive and neurodevelopment disorders. The use of AEDs is the mainstay in treating epilepsy in TSC, with close to all patients having at least one dispense during the study period. Despite a high prevalence of refractory epilepsy, the use of alternative treatments such as surgery, ketogenic diet, VNS, or mTOR-inhibitors remain low. There is a need to understand how to best treat epilepsy and other major manifestations of TSC to avoid the high morbidity and mortality in this patient group.
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